c-Rel and its many roles in cancer: an old story with new twists

Por Hunter, Jill E, Leslie, Jack, Perkins, Neil D
Publicado no Br J Cancer (2016)

Ionizing radiation-induced NF-κB activation requires PARP-1 function to confer radio-resistance

Por Veuger, Stephany J., Hunter, Jill E., Durkacz, Barbara W.
Publicado em 2008

NF-κB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699

Por Hunter, Jill E., Willmore, Elaine, Irving, Julie A. E., Hostomsky, Zdenek, Veuger, Stephany J., Durkacz, Barbara W.
Publicado em 2011

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia

Por Herriott, Ashleigh, Tudhope, Susan J., Junge, Gesa, Rodrigues, Natalie, Patterson, Miranda J., Woodhouse, Laura, Lunec, John, Hunter, Jill E., Mulligan, Evan A., Cole, Michael, Allinson, Lisa M., Wallis, Jonathan P., Marshall, Scott, Wang, Evelyn, Curtin, Nicola J., Willmore, Elaine
Publicado no Oncotarget (2015)

The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma

Por Walton, Mike I., Eve, Paul D., Hayes, Angela, Henley, Alan T., Valenti, Melanie R., De Haven Brandon, Alexis K., Box, Gary, Boxall, Kathy J., Tall, Matthew, Swales, Karen, Matthews, Thomas P., McHardy, Tatiana, Lainchbury, Michael, Osborne, James, Hunter, Jill E., Perkins, Neil D., Aherne, G. Wynne, Reader, John C., Raynaud, Florence I., Eccles, Suzanne A., Collins, Ian, Garrett, Michelle D.
Publicado no Oncotarget (2015)